Targeted agent selumetinib shows promise in biliary cancer
Monday, April 25, 2011 - 16:00
in Health & Medicine
The experimental agent selumetinib has shown promising results in people with advanced biliary cancer, according to a multi-institutional clinical trial led by cancer researchers at The Ohio State University.